EP0927033A4 - - Google Patents

Info

Publication number
EP0927033A4
EP0927033A4 EP97932417A EP97932417A EP0927033A4 EP 0927033 A4 EP0927033 A4 EP 0927033A4 EP 97932417 A EP97932417 A EP 97932417A EP 97932417 A EP97932417 A EP 97932417A EP 0927033 A4 EP0927033 A4 EP 0927033A4
Authority
EP
European Patent Office
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97932417A
Other versions
EP0927033A1 (fr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/674,481 external-priority patent/US6040342A/en
Priority claimed from US08/883,219 external-priority patent/US6071923A/en
Application filed filed Critical
Publication of EP0927033A4 publication Critical patent/EP0927033A4/xx
Publication of EP0927033A1 publication Critical patent/EP0927033A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP97932417A 1996-07-02 1997-07-01 Retinoyloxy-alkylene butyrates (substitues) utiles pour le traitement du cancer et autres maladies proliferatives Withdrawn EP0927033A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/674,481 US6040342A (en) 1994-09-16 1996-07-02 Retinoyloxy (alkyl-substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
US674481 1996-07-02
US08/883,219 US6071923A (en) 1994-09-16 1997-06-26 Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
PCT/US1997/011452 WO1998000127A1 (fr) 1996-07-02 1997-07-01 Retinoyloxy-alkylene butyrates (substitues) utiles pour le traitement du cancer et autres maladies proliferatives
2000-02-22

Publications (2)

Publication Number Publication Date
EP0927033A4 true EP0927033A4 (fr) 1999-07-07
EP0927033A1 EP0927033A1 (fr) 1999-07-07

Family

ID=27101163

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97932417A Withdrawn EP0927033A1 (fr) 1996-07-02 1997-07-01 Retinoyloxy-alkylene butyrates (substitues) utiles pour le traitement du cancer et autres maladies proliferatives

Country Status (6)

Country Link
EP (1) EP0927033A1 (fr)
JP (1) JP2002514161A (fr)
AU (1) AU3588097A (fr)
CA (1) CA2258593A1 (fr)
IL (1) IL127739A0 (fr)
WO (1) WO1998000127A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6110970A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Nitrogen-containing oxyalkylene esters and uses thereof
MXPA00010070A (es) * 1998-04-15 2004-03-10 Lexigen Pharm Corp Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis.
CA2328081A1 (fr) * 1998-04-17 1999-10-28 Lexigen Pharmaceuticals Corporation Amelioration des reponses immunitaires dont la mediation est assuree par une proteine de fusion anticorps-cytokine, via coadministration de cette proteine de fusion avec un inhibiteur de prostaglandine
US6720445B2 (en) 2000-12-21 2004-04-13 Beacon Laboratories, Inc. Acetyloxymethyl esters and methods for using the same
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
SE0101702D0 (sv) 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
EP1491188A1 (fr) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Utilisation topique de l'acide valproique pour traiter des maladies de la peau
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
JP4921351B2 (ja) * 2004-03-26 2012-04-25 ディーエスエム アイピー アセッツ ビー．ブイ． レチノイドと組み合せたｈｄａｃインヒビターを含む組成物
AU2006270322A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR20120030383A (ko) 2009-04-22 2012-03-28 메르크 파텐트 게엠베하 변형된 ＦｃＲｎ 결합 자리를 갖는 항체 융합 단백질

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677120A (en) * 1985-07-31 1987-06-30 Molecular Design International Topical prodrugs for treatment of acne and skin diseases
WO1989000157A1 (fr) * 1987-06-29 1989-01-12 Molecular Design International, Inc. Esters d'acide 13-trans retinoique
WO1990006751A1 (fr) * 1988-12-14 1990-06-28 Molecular Design International, Inc. Utilisations dermatologiques de retinoides non irritants
EP0449099A2 (fr) * 1990-03-27 1991-10-02 F. Hoffmann-La Roche Ag Dérivés rétinoides, leur préparation et leur utilisation dans médicaments
US5710176A (en) * 1994-09-16 1998-01-20 Bar-Ilan University Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK498487A (da) * 1986-10-06 1988-04-07 Hoffmann La Roche Hidtil ukendte retinoider

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677120A (en) * 1985-07-31 1987-06-30 Molecular Design International Topical prodrugs for treatment of acne and skin diseases
WO1989000157A1 (fr) * 1987-06-29 1989-01-12 Molecular Design International, Inc. Esters d'acide 13-trans retinoique
WO1990006751A1 (fr) * 1988-12-14 1990-06-28 Molecular Design International, Inc. Utilisations dermatologiques de retinoides non irritants
EP0449099A2 (fr) * 1990-03-27 1991-10-02 F. Hoffmann-La Roche Ag Dérivés rétinoides, leur préparation et leur utilisation dans médicaments
US5710176A (en) * 1994-09-16 1998-01-20 Bar-Ilan University Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9800127A1 *

Also Published As

Publication number Publication date
AU3588097A (en) 1998-01-21
JP2002514161A (ja) 2002-05-14
IL127739A0 (en) 1999-10-28
EP0927033A1 (fr) 1999-07-07
WO1998000127A1 (fr) 1998-01-08
CA2258593A1 (fr) 1998-01-08

Similar Documents

Publication Publication Date Title
AR026661A2 (fr)
BRPI9713914B8 (fr)
BR9603859A (fr)
BR7600721U (fr)
BR7601346U (fr)
CN3045853S (fr)
CN3046158S (fr)
CN3040543S (fr)
CN3040805S (fr)
CN3041207S (fr)
CN3041374S (fr)
CN3041383S (fr)
CN3042289S (fr)
CN3043305S (fr)
CN3044168S (fr)
CN3044346S (fr)
CN3044347S (fr)
CN3044348S (fr)
CN3044349S (fr)
CN3045208S (fr)
CN3045530S (fr)
CN3045806S (fr)
CN3047312S (fr)
CN3045880S (fr)
CN3045888S (fr)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990104

A4 Supplementary search report drawn up and despatched

Effective date: 19990401

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19990104;LT PAYMENT 19990104;LV PAYMENT 19990104;RO PAYMENT 19990104;SI PAYMENT 19990104

17Q First examination report despatched

Effective date: 20010710

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020201